Truqap, the breast cancer drug which was on trial has failed to meet its main goal, the drug manufacturer AstraZeneca said on Tuesday. It said that its breast cancer drug, Truqap, in combination ...

AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...

Bloomberg / Contributor / Getty Images A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a ...

Also Read: AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results. An improvement in patient-reported outcomes was also seen. The safety profile of ...

(Reuters) -AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer ...

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...

AstraZeneca (NASDAQ:AZN) announced Tuesday that its blockbuster immunotherapy Imfinzi failed in a late-stage trial for patients with early-stage non-small cell lung cancer whose tumors have been ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to ...